摘要:
The present invention is directed to a process for producing non-genotoxic Diacetylrhein (Diacerein), comprising: i) transformation of raw Diacerein (or raw Rhein), into a water-soluble salt; ii) adsorption of the salt Diacerein (or Rhein) solution on a hydrophobic resin; iii) washing with an appropriate solvent to eliminate the impurities (in particular the genotoxic impurities); iv) elution to recover Diacereinor Rhein; v) if the process is applied to Rhein, its transformation to Diacerein by acetylation; vi) acidification of purified Diacerein and its recovery, and drying. The invention is also directed to non-genotoxic Diacerein obtained by the process of the invention, in which the total content of genotoxic impurities is below 1ppm, and suitable for the preparation of pharmaceutical formulations, in particular capsules, for human and veterinary use, in agreement with the current Health Authorities request.
摘要:
Rhein analogues that exhibit anti-proliferative activity, particular against cancer cells, are described herein. In some embodiments, the compounds contain a flat or planar ring system. Such rings system by facilitate non-covalent binding of the compounds to the DNA complex, such as by intercalation. In some embodiment, the compounds contain a flat or planar ring system as described above and one or more substituents which are alkylating moieties, electrophilic groups or Michael acceptors or groups which contain one or more alkylating moieties, electrophilic groups and/or Michael acceptors. The compounds described herein can also contain one more functional groups to improve the solubility of the compounds.
摘要:
The conjugates of present invention are formed by the combination of rhein or their analogues with the organic bases or amino acids in molecular force between them. The methods for preparing the conjugates and their uses for manufacturing medicines in the treatment of diabetic nephrosis, recovery of gastrointestinal function and prevention of intestinal adhesion, as well as treatment of osteoarthritis, rheumatic arthritis and rheumatoid arthritis are also described. Rhein or their analogues as the left part of general formula (I) is selected from (1) the compounds of rhein or their analogues, in which one or two substituents of R2~R3 and R6~R7 are COOH at least two substituents of R1~8 are -H; or (2) the rhein-containing extract derived from plants. In general formula (I), M represents nitrogen-containing organic bases or basic amino acids.
摘要:
The invention concerns a new process for the preparation of high purity diacerein, by oxidisation of the protected aloe-emodin in the presence of an oxidising system and radical catalyst and subsequent substitution of the protector groups with acetyl groups.
摘要:
Procédé de synthèse d'un composé de formule (1) dans laquelle R 1 représente un groupement hydroxyle ou acétoxy, caractérisé en ce qu' il comprend : - une étape de métallation du cycle aromatique d'un composé de formule (2) dans laquelle R 2 et R 3 représentent indépendamment un groupement alkyle en C 1 à C 4 , sélectivement en position ortho du substituant -OR 2 ; - la réaction du composé métallé ainsi obtenu avec un composé de formule (3) dans laquelle R 2 est tel que défini ci-dessus, et R 4 est un groupement électrophile pouvant être choisi dans le groupe comprenant les groupements -CHO, -COX avec X=Cl, Br, I, -COCN, -CONCH 3 OCH 3 , -CON(R) 2 , -COOR ou R représente un groupement alkyle en C 1 à C 4 et est de préférence un groupement -CHO ou -COCl; - suivie par des étapes d'hydrolyse acide, de réduction, de cyclisation et d'oxydation conduisant au composé (1).
摘要:
The present invention discloses medicaments that are selectin-ligand structural mimetics that bind to certain selectins wherein the mimetics may lack the sialic acid and/or fucose of the natural selecting ligand, sialyl Lewis (sLe ), but have a structure capable of mimicking the structural features necessary for selectin recognition. In particular, the invention compounds mimic the key structural features of the oligosaccharides responsible for selectin-mediated cell adhesion. These features consist of the charge-distance-coordination relationship between the carboxylic acid functionality of sialic acid at a distance of 8-12 angstroms of the L-fucose moiety. The invention compounds are disalicylate, its analogs, and disalicylate-based C-glycoside compounds. The present invention also discloses methods of treating selectin-mediated disorders comprising administering the compounds disclosed.
摘要:
The present invention is directed to a process for producing non-genotoxic Diacetylrhein (Diacerein), comprising: i) transformation of raw Diacerein (or raw Rhein), into a water-soluble salt; ii) adsorption of the salt Diacerein (or Rhein) solution on a hydrophobic resin; iii) washing with an appropriate solvent to eliminate the impurities (in particular the genotoxic impurities); iv) elution to recover Diacereinor Rhein; v) if the process is applied to Rhein, its transformation to Diacerein by acetylation; vi) acidification of purified Diacerein and its recovery, and drying. The invention is also directed to non-genotoxic Diacerein obtained by the process of the invention, in which the total content of genotoxic impurities is below 1ppm, and suitable for the preparation of pharmaceutical formulations, in particular capsules, for human and veterinary use, in agreement with the current Health Authorities request.
摘要:
A compound of general formula (I): wherein Xi is H or COR 1 and X 2 is H or COR 2 but X 1 and X 2 are not both H; R 1 and R 2 are the same or different and are each C 1-4 alkyl substituted with R 3 , or a four to seven-membered ring which can be optionally substituted with R 8 and can contain one or more additional heteroatoms selected from O, S(O)n and NR 9 ; R 3 is F, CF 3 , OR 4 , NR 5 R 6 or S(O) n R 7 ; R 4 , R 5 and R 6 are the same or different and are each H or C 1-4 alkyl optionally substituted with R 3 , or NR 5 R 6 is a C 4-6 heterocycloalkyl ring containing one or more heteroatoms selected from O, NR 8 and S(O) n ; each n is 0-2; R 7 is C 1-4 alkyl; R 8 is as defined for R 3 or C 1-4 alkyl optionally substituted with R 3 or halogen; R 9 is H or C 1-4 alkyl; Y is NR 9 R 10 R 11 ; and R 10 and R 11 are the same or different and are each H or C 1-6 alkyl optionally substituted with R 3 or halogen, or NR 10 R 11 is a four to seven membered ring which can be optionally substituted with R 8 or COR 1 , and can contain one or more additional heteroatoms selected from O, S(O) n and NR 9 ; and hydrates thereof.
摘要翻译:通式(I)的化合物:其中X 1是H或COR 1 X和X 2是H或COR 2,但X 1和X 2不同时为H; R 1和R 2各自相同或不同,并且各自是被R 3 3取代的C 1-4烷基, 或者可以任选地被R 8'取代的4-7元环,并且可以含有一个或多个选自O,S(O)n和NR 9的另外的杂原子 SUB >; R 3是F,CF 3或OR 4,NR 5 R 6, 或S(O)n R 7 R 7; R 4,R 5和R 6相同或不同,各自为H或C 1-4烷基, 任选被R 3 3或NR 5 R 6取代的烷基是含有一个的C 4-6 - 杂环烷基环 或更多选自O,NR 8和S(O)n的杂原子。 每个n为0-2; R 7是C 1-4烷基; R 8如R 3或C 1-4烷基所定义,任选被R 3或卤素取代; R 9是H或C 1-4烷基; Y为NR 9 R 10 R 11; 且R 10和R 11相同或不同,并且各自为任选被R 3取代的H或C 1-6烷基 或卤素,或NR 10 R 11是可以任选被R 8或COR取代的四元至七元环 并且可以含有一个或多个选自O,S(O)n和NR 9的另外的杂原子。 及其水合物。
摘要:
The strain of the microorganism Penicillium oxalicum var. Armeniaca CCM 8242 produces an anthraquinonyl carboxylic acid derivative of structural formula (I), which may be used as a colorant, especially as a food colorant or cosmetic colorant.
摘要:
The present invention discloses medicaments that are selectin-ligand structural mimetics that bind to certain selectins wherein the mimetics may lack the sialic acid and/or fucose of the natural selecting ligand, sialyl Lewis (sLe ), but have a structure capable of mimicking the structural features necessary for selectin recognition. In particular, the invention compounds mimic the key structural features of the oligosaccharides responsible for selectin-mediated cell adhesion. These features consist of the charge-distance-coordination relationship between the carboxylic acid functionality of sialic acid at a distance of 8-12 angstroms of the L-fucose moiety. The invention compounds are disalicylate, its analogs, and disalicylate-based C-glycoside compounds. The present invention also discloses methods of treating selectin-mediated disorders comprising administering the compounds disclosed.